MGMT |
promoter methylation |
response to TMZ treatment |
Hegi et al., 2005Hegi ME, Diserens AC, Gorlia T, Hamou MF, De Tribolet N, Weller M, Kros JM, Hainfellner JA, Mason W, Mariani L et al. (2005) MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 352:8.; Hegi et al., 2008Hegi ME, Liu L, Herman JG, Stupp R, Wick W, Weller M, Mehta MP and Gilbert MR (2008) Correlation of O6-methylguanine methyltransferase (MGMT) promoter methylation with clinical outcomes in glioblastoma and clinical strategies to modulate MGMT activity. J Clin Oncol 26:4189-4199.; Stupp et al., 2009Stupp R, Hegi ME, Mason WP, van den Bent MJ, Taphoorn MJ, Janzer RC, Ludwin SK, Allgeier A, Fisher B, Belanger K et al. (2009) Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 10:459-466.; Binabaj et al., 2018Binabaj MM, Bahrami A, ShahidSales S, Joodi M, Joudi Mashhad M, Hassanian SM, Anvari K and Avan A (2018) The prognostic value of MGMT promoter methylation in glioblastoma: A meta-analysis of clinical trials. J Cell Physiol 233:378-386.
|
APNG |
overexpression |
controversial |
Agnihotri et al., 2012Agnihotri S, Gajadhar AS, Ternamian C, Gorlia T, Diefes KL, Mischel PS, Kelly J, McGown G, Thorncroft M, Carlson BL et al. (2012) Alkylpurine-DNA-N-glycosylase confers resistance to temozolomide in xenograft models of glioblastoma multiforme and is associated with poor survival in patients. J Clin Invest 122:253-266.; Fosmark et al., 2017Fosmark S, Hellwege S, Dahlrot RH, Jensen KL, Derand H, Lohse J, Sorensen MD, Hansen S and Kristensen BW (2017) APNG as a prognostic marker in patients with glioblastoma. PLoS One 12:e0178693.
|
HJURP |
overexpression |
poor outcome, worse overall survival |
de Tayrac et al., 2011de Tayrac M, Aubry M, Saikali S, Etcheverry A, Surbled C, Guenot F, Galibert MD, Hamlat A, Lesimple T, Quillien V et al. (2011) A 4-gene signature associated with clinical outcome in high-grade gliomas. Clin Cancer Res 17:317-327.; Valente et al., 2013Valente V, Serafim RB, de Oliveira LC, Adorni FS, Torrieri R, Tirapelli DP, Espreafico EM, Oba-Shinjo SM, Marie SK, Paco-Larson ML et al. (2013) Modulation of HJURP (Holliday Junction-Recognizing Protein) levels is correlated with glioblastoma cells survival. PLoS One 8:e62200.
|
DDB2 |
reduction |
reduced survival |
de Sousa et al., 2017de Freitas LM, Serafim RB, de Sousa JF, Moreira TF, Dos Santos CT, Baviera AM, Valente V, Soares CP and Fontana CR (2017) Photodynamic therapy combined to cisplatin potentiates cell death responses of cervical cancer cells. BMC Cancer 17:123.
|
BRCA2 |
overexpression |
reduced survival |
de Sousa et al., 2017de Sousa JF, Torrieri R, Serafim RB, Di Cristofaro LF, Escanfella FD, Ribeiro R, Zanette DL, Paco-Larson ML, da Silva WA, Jr., Tirapelli DP et al. (2017) Expression signatures of DNA repair genes correlate with survival prognosis of astrocytoma patients. Tumour Biol 39:1010428317694552.
|
BRIP1 |
overexpression |
reduced survival |
de Sousa et al., 2017de Sousa JF, Torrieri R, Serafim RB, Di Cristofaro LF, Escanfella FD, Ribeiro R, Zanette DL, Paco-Larson ML, da Silva WA, Jr., Tirapelli DP et al. (2017) Expression signatures of DNA repair genes correlate with survival prognosis of astrocytoma patients. Tumour Biol 39:1010428317694552.
|
XRCC3 |
polymorphism |
increased GBM susceptibility |
Custodio et al., 2012Custodio AC, Almeida LO, Pinto GR, Santos MJ, Almeida JR, Clara CA, Rey JA and Casartelli C (2012) Variation in DNA repair gene XRCC3 affects susceptibility to astrocytomas and glioblastomas. Genet Mol Res 11:332-339.
|
EXO1 |
polymorphism |
increased GBM susceptibility |
Chang et al., 2008Chang JS, Yeh RF, Wiencke JK, Wiemels JL, Smirnov I, Pico AR, Tihan T, Patoka J, Miike R, Sison JD et al. (2008) Pathway analysis of single-nucleotide polymorphisms potentially associated with glioblastoma multiforme susceptibility using random forests. Cancer Epidemiol Biomarkers Prev 17:1368-1373.
|
EXO1 |
overexpression |
reduced survival |
de Sousa et al., 2017de Sousa JF, Torrieri R, Serafim RB, Di Cristofaro LF, Escanfella FD, Ribeiro R, Zanette DL, Paco-Larson ML, da Silva WA, Jr., Tirapelli DP et al. (2017) Expression signatures of DNA repair genes correlate with survival prognosis of astrocytoma patients. Tumour Biol 39:1010428317694552.
|
NEIL3 |
overexpression |
reduced survival |
de Sousa et al., 2017de Sousa JF, Torrieri R, Serafim RB, Di Cristofaro LF, Escanfella FD, Ribeiro R, Zanette DL, Paco-Larson ML, da Silva WA, Jr., Tirapelli DP et al. (2017) Expression signatures of DNA repair genes correlate with survival prognosis of astrocytoma patients. Tumour Biol 39:1010428317694552.
|
MSH6 |
mutations |
controversial |
Hunter et al., 2006Hunter C, Smith R, Cahill DP, Stephens P, Stevens C, Teague J, Greenman C, Edkins S, Bignell G, Davies H et al. (2006) A hypermutation phenotype and somatic MSH6 mutations in recurrent human malignant gliomas after alkylator chemotherapy. Cancer Res 66:3987-3991.; Maxwell et al., 2008Maxwell JA, Johnson SP, McLendon RE, Lister DW, Horne KS, Rasheed A, Quinn JA, Ali-Osman F, Friedman AH, Modrich PL et al. (2008) Mismatch repair deficiency does not mediate clinical resistance to temozolomide in malignant glioma. Clin Cancer Res 14:4859-4868.; Yip et al., 2009Yip S, Miao J, Cahill DP, Iafrate AJ, Aldape K, Nutt CL and Louis DN (2009) MSH6 mutations arise in glioblastomas during temozolomide therapy and mediate temozolomide resistance. Clin Cancer Res 15:4622-4629.; Sun et al., 2018Sun Q, Pei C, Li Q, Dong T, Dong Y, Xing W, Zhou P, Gong Y, Zhen Z, Gao Y et al. (2018) Up-regulation of MSH6 is associated with temozolomide resistance in human glioblastoma. Biochem Biophys Res Commun 496:1040-1046.
|